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Background/aim: Respiratory and peripheral muscle strength are reduced in chronic obstructive pulmonary disease (COPD). There is
a well-known correlation between handgrip strength (HGS) and strenght extremity muscles. Our aim in this study was to measure HGS
and investigate the related factors in COPD patients with exacerbation.
Materials and methods: Subjects with COPD exacerbation (n = 101) and stable COPD (n = 22), and subjects without COPD (n = 201),
were enrolled in this study. Age, sex, and body mass index were similar. HGS was measured using a Vigorimeter. Pulmonary function
tests and 6-min walk tests were performed.
Results: The mean HGS was significantly lower in subjects with COPD exacerbation than those with stable COPD and subjects without
COPD. The mean HGS was similar between stable COPD and non-COPD subjects. The mean 6-min walk distance (6MWD) was
significantly lower in subjects with COPD exacerbation than stable COPD. There was a significant correlation between HGS and 6MWD
but no correlation between HGS and pulmonary function tests.
Conclusion: In subjects with COPD exacerbation, the HGS was lower than that of stable COPD patients, and this difference was not
explained by age, comorbidities, severity of obstruction, or smoking. Physical inactivity and steroid use during exacerbation might be
possible factors affecting HGS. HGS was moderately correlated with 6MWD in cases of exacerbation. It may be used as a measure of
muscle performance in COPD exacerbation, especially when the 6-min walk test cannot be performed.
Key words: Chronic obstructive pulmonary disease, hand grip strength, 6-min walk distance, exacerbation, muscle strength

1. Introduction
Chronic obstructive pulmonary disease (COPD) has
several systemic manifestations, including skeletal muscle
dysfunction, which increases the risk of morbidity and
mortality (1). The strength of skeletal and respiratory
muscles is reduced in COPD compared to the normal
population (1–4). The weakness of the quadriceps muscle
is observed in 70% of subjects with chronic lung disease (3)
and is more prominent than weakness of upper extremity
muscles such as the pectoralis major and latissimus dorsi
in COPD (5). Maximal strength of the diaphragm is 30%
to 40% lower in cases of COPD (1).
Handgrip strength (HGS), which is a simple and
inexpensive measurement, is not only a direct measure of
hand muscle strength but also a good indicator of overall
muscle strength in elderly subjects (6,7). It was shown to

be correlated with the strength of other muscles such as
the quadriceps (8), upper limb muscles (9), and respiratory
muscles (8,9) in COPD. Low HGS was independently
associated with a higher risk for exacerbations in smokers
with stable COPD (10). It was demonstrated that HGS was
associated with cardiac function (11) and walking distance
(8) in COPD cases.
The 6-min walk test (6MWT) is an objective and
inexpensive method used to assess submaximal exercise
capacity. Muscle strength in the lower limbs was shown
to be an important factor in determining the 6-min
walk distance (6MWD) (8,12). The 6MWD was also
significantly correlated with handgrip force in individuals
with stable COPD (8,12,13).
To our knowledge, there is no study comparing the
handgrip strength of COPD subjects during exacerbation
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with those of stable COPD patients and subjects without
COPD. The aim of this study was to measure HGS and
investigate the associated factors, including 6MWD, in
subjects with acute exacerbation of COPD.
2. Materials and methods
This cross-sectional study was approved by the Gazi
University Ethics Committee (Date/No: 09.03.2015/123).
All participants gave their written informed consent for
the study.
2.1. Participants
Participants were recruited among subjects with COPD
registered in pulmonary rehabilitation medical records
between January 2010 and December 2014. Subjects with
acute exacerbation of COPD (n = 101) and subjects with
stable COPD (n = 22) were enrolled in the study. The
diagnosis of COPD was made according to the Global
Initiative for Chronic Obstructive Lung Disease (GOLD)
criteria (14). For the non-COPD group, individuals
without COPD (n = 201) were recruited among patients
admitted to the physical medicine and rehabilitation
outpatient clinic for other problems such as meniscal
degeneration, knee osteoarthritis, and low back pain.
The exclusion criteria were the presence of cancer,
neurologic or rheumatologic disease, advanced heart
disease (New York Heart Association Classification stages
III or IV), or any other condition that might adversely
influence upper extremity functions and the cooperation
of the individual.
2.2. Measures
Demographic variables including age, sex, height, weight,
body mass index (BMI), years of education, and systemic
illnesses were recorded for all subjects. The duration of
COPD, smoking status, pulmonary function, other related
clinical parameters, 6MWD, and length of inpatient stay
(for the exacerbation group) were recorded for the subjects
with COPD.
Handgrip strength was measured using the handheld
Vigorimeter apparatus (Riester, Dynatest, Jungingen,
Germany) according to the procedure recommended by
the American Society of Hand Therapists (15). After the
explanation of the procedure, subjects were seated placing
their arms by their sides with the elbow flexed to 90°, the
forearm mid-prone, and the wrist in neutral position.
Subjects were asked to squeeze the Vigorimeter with
maximal effort to measure maximal voluntary HGS (in
bars) for both the dominant and the nondominant hand.
Standard verbal encouragement was given to every patient.
Three trials were performed with a 1-min rest between
trials and the highest value was used for the analysis.
Pulmonary function tests were performed using a
Sensormedics Vmax Series 20C Respiratory Analyzer
according to the criteria of the European Respiratory
Society for COPD subjects (16). Forced expiratory volume

in 1 s (FEV1), forced vital capacity (FVC), and FEV1/FVC
ratios were recorded.
The 6MWT was performed with COPD subjects
according to the American Thoracic Society guidelines
(17) in a 30-m corridor. The subjects were asked to walk
as much distance as they could within 6 min. The 6MWD
was recorded in meters.
Statistical analysis was performed using SPSS 20.0 for
Windows (IBM Corp., Armonk, NY, USA). Continuous
variables were presented as means and standard deviations.
Categorical data were presented as percentages. Statistical analysis was performed using ANOVA with post hoc
Tukey analysis and Student’s t-test as appropriate. Pearson’s correlation coefficient was computed to analyze the
correlation between HGS and other parameters in COPD
subjects with exacerbation. The comparison of categorical
data was performed using Fisher’s exact test. The variables
of the COPD subjects with exacerbation who could and
could not complete the 6MWT were evaluated using Student’s t test or the chi-square test for continuous and categorical variables, respectively. Missing data were removed
and the remaining data were analyzed. The sample size was
calculated using G*Power with regard to Vilaro et al. (18)
and it was seen that the recruitment of 119 stable and 119
exacerbated subjects was necessary. Statistical significance
was accepted as P < 0.05.
3. Results
One hundred and eleven subjects with COPD exacerbation,
27 subjects with stable COPD, and 252 non-COPD
subjects were potentially eligible for the study. After the
confirmation of the eligibility of the participants, 101
subjects with COPD exacerbation, 22 subjects with stable
COPD, and 201 non-COPD subjects were enrolled. The
Figure shows the flow diagram.
The demographic and clinical features of the subjects
are presented in Table 1. Age, sex, and BMI were similar
among the groups. Education years were higher in the
stable COPD subjects than the other groups (P = 0.004).
The prevalence of hypertension and heart disease was
significantly different among the groups and the difference
was due to the non-COPD group. Subgroup analysis did
not reveal any statistically significant differences between
the subjects with COPD exacerbation and stable COPD.
Table 2 demonstrates clinical features of the COPD
subjects. The respiratory parameters (FEV1, FEV1/FVC)
of the exacerbation group were lower than those of the
group with stable COPD; however, the difference did not
reach statistical significance.
HGS measurements of the dominant and nondominant
hands and 6MWD parameters are given in Table 3. The
mean HGS was significantly lower in the COPD subjects
with exacerbation than the stable COPD and non-COPD
subjects (P < 0.001). The mean 6MWD was significantly
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Figure. Flow diagram of the study.

lower in subjects with COPD exacerbation than those with
stable COPD (P = 0.003).
Table 4 shows the correlations between HGS (the
mean of dominant and nondominant HGS) and the other
parameters in COPD subjects with exacerbation. HGS
demonstrated a moderate correlation with 6MWD and a
weak negative correlation with age and length of inpatient
stay. There was no correlation between HGS and FEV1 or
COPD duration.
The subjects with COPD exacerbation were divided
according to their ability to complete the 6MWT. Twenty
subjects could not even walk and 23 subjects stopped
walking before 3 min, while 58 subjects were able to
complete the test. Table 5 shows the characteristics of two
groups (completed and not completed). The subjects who
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could not complete the 6MWT were older, and women
with longer length of stay and COPD duration had lower
HGS. BMI and respiratory parameters were not different
between the two groups.
4. Discussion
In this study, COPD subjects with exacerbation showed
significantly lower HGS compared to the stable COPD
and non-COPD subjects. In the COPD subjects with
exacerbation, the mean HGS showed a moderate
correlation with 6MWD and a weak negative correlation
with age and length of stay. Nearly half (43%) of the COPD
subjects with exacerbation could not complete the 6MWT
and had lower HGS than the individuals who completed
the test.
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Table 1. Demographic characteristics of the subjects.

Age (years)

COPD – exacerbated (n=101),
mean ± SD or %
68.3 ± 9.1

COPD – stable (n = 22),
mean ± SD or %
65.6 ± 8.8

Non-COPD (n = 201),
mean ± SD or %
66.6 ± 6.4

Men (%)

74

82

82

0.417

P
0.082

BMI (kg/m )

26.36 ± 7.67

27.78 ± 5.86

27.90 ± 3.31

0.052

Education (years)

6.9 ± 4.6

8.8 ± 5.2*

6.1 ± 2.9

0.004

Heart disease (%)

46

36

10*

<0.001

Hypertension (%)

56

46

23*

<0.001

Diabetes mellitus (%)

20

14

25

0.314

2

COPD: Chronic obstructive pulmonary disease. SD: Standard deviation. BMI: Body mass index.
*: The group from which the difference originates.
Table 2. Clinical features of COPD subjects.

Stages (GOLD), %
I
II
III
IV
Smoking status (%)

COPD – exacerbated (n = 101),
mean ± SD or %
7.6 ± 6.7
38.9 ± 14.6
(n = 90)
53.9 ± 10.3
(n = 90)
(n = 90)
1.1
18.9
47.8
32.2
26

COPD – stable (n = 22),
mean ± SD or %
8.4 ± 6.9
45.8 ± 18.6
(n = 19)
58.9 ± 12.5
(n = 19)
(n = 19)
5.2
21.1
57.9
15.7
24

0.936

Smoking (pack years)

54.7 ± 35.2

57.3 ± 31.0

0.779

COPD duration (years)
FEV1 (%)
FEV1/FVC

P
0.661
0.108
0.084

0.258

COPD: Chronic obstructive pulmonary disease. SD: Standard deviation. FEV1: Forced expiratory
volume in 1 s. FVC: Forced vital capacity.
Table 3. Measurements of handgrip strength and 6MWD.

HGS – dominant (bar)

COPD – exacerbated (n = 101),
mean ± SD or %
0.47 ± 0.17*

COPD – stable (n = 22),
mean ± SD or %
0.57 ± 0.16

Non-COPD (n = 201),
mean ± SD or %
0.55 ± 0.16

HGS – nondominant (bar)

0.44 ± 0.16*

0.55 ± 0.16

0.52 ± 0.16

<0.001

6MWD (m)

232.4 ± 149.3

335.9 ± 120.0

NA

0.003

P
<0.001

COPD: Chronic obstructive pulmonary disease. SD: Standard deviation. HGS: Handgrip strength. 6MWD: Six-minute walk
distance.
NA: Not applied
*: The group from which the difference originates.

HGS was measured in cases of stable COPD in previous
studies; Shah et al. found significantly lower HGS and
endurance (9), whereas Heijdra et al. found similar HGS
in patients with stable COPD and age-matched healthy

subjects (19). Similar to Heijdra et al., our results revealed
comparable HGS in stable COPD and non-COPD subjects.
In a cross-sectional study, Martinez et al. found that a 1-kg
reduction in HGS was associated with an increased risk
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Table 4. Correlation between mean handgrip strength and other parameters in COPD subjects
with exacerbation.
6MWD Age
HGS (bar)
6MWD (m)
Age (years)
COPD duration (years)
BMI (kg/m2)
FEV1 (%)

r*

0.516

P** <0.001

COPD duration BMI

FEV1

LOS

–0.250 –0.158

0.086

-0.070

–0.247

0.012

0.395

0.509

0.015

0.134

r

–0.269 –0.249

0.043

0.158

–0.151

P

0.007

0.670

0.137

0.141

0.017

r

0.188

–0.151 0.252

–0.107

P

0.076

0.136

0.017

0.302

r

-0.114

0.233

P

0.311

0.031

r

0.273

–0.083

P

0.010

0.422

r

–0.088

P

0.422

HGS: Handgrip strength. 6MWD: Six-minute walk distance. COPD: Chronic obstructive
pulmonary disease. BMI: Body mass index. FEV1: Forced expiratory volume in 1 s. LOS: Length
of inpatient stay
*r: Pearson correlation. **: P < 0.05 is significant.

Table 5. Comparison of COPD subjects with exacerbation who could and could not complete the
6MWT.

Age (years)

Completed (n = 58),
mean ± SD or %
67 ± 8

Not completed (n = 43),
P
mean ± SD or %
71 ± 10
0.033

Men (%)

68

32

<0.001

BMI (kg/m )

27.3 ± 6.8

25.1 ± 8.7

0.156

COPD duration (years)

6±6

9±7

0.043

FEV1 (%)

40.6 ± 13.1

36.5 ± 16.3

0.193

Length of inpatient stay (days)

12 ± 6

15 ± 7

0.033

HGS (bar)

0.53 ± 0.14

0.36 ± 0.13

<0.001

6MWD (m)

317 ± 99

31 ± 48

<0.001

2

SD: Standard deviation. BMI: Body mass index. COPD: Chronic obstructive pulmonary disease.
FEV1: Forced expiratory volume in 1 s. HGS: Handgrip strength. 6MWD: Six-minute walk distance.

of exacerbation by 5% in stable COPD (10). They did not
measure HGS directly in the exacerbation period. Vilaro et
al. observed that HGS was weaker in COPD patients with
exacerbation than those with stable COPD. In our study,
we primarily enrolled COPD subjects with exacerbation
and found that their muscle strength was lower than that
of stable COPD and non-COPD subjects.
Several factors related to skeletal muscle dysfunction
in COPD have been described, including comorbidities,
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smoking, aging, inactivity, exacerbation, hypoxia, systemic
oxidative stress, systemic inflammation, and medications
such as corticosteroids (20–22). In our study, age was
similar among the three groups; the mean age of the
subjects with COPD exacerbation was not different from
that of the stable COPD or non-COPD subjects. Therefore,
lower HGS in the exacerbation group compared to the
subjects with stable COPD could not be attributed to
older age. We observed that presence of chronic diseases,
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smoking status, and pulmonary function tests were similar
in the subjects with exacerbated and stable COPD. The
similarity of these factors in our study suggested that we
exclude them as confounding parameters for lower HGS
in exacerbation.
Systemic corticosteroids used in exacerbated or
advanced COPD can induce both acute and chronic
myopathy (20–23). In our study, all the patients with
exacerbation used oral steroids for a short period,
beginning with 32 mg decreasing slowly and ceasing at 10
days, which was the standardized treatment protocol. The
steroids used during the treatment of exacerbation might
have contributed to the reduced HGS in our exacerbation
group, as well.
Physical inactivity due to breathlessness and old
age (20) contributes to muscle atrophy and weakness in
COPD subjects (1,22). In our study, the subjects with
COPD exacerbation demonstrated lower levels of physical
activity (shorter 6MWD) than the similarly aged stable
COPD subjects. The subjects who could not complete
the 6MWT in exacerbation were older and had weaker
muscle strength, a longer duration of disease, and a
longer hospital stay, all of which indicated higher disease
severity. This reduction in physical activity in COPD is in
accordance with the literature. Physical inactivity further
decreases muscle strength and hence increases disability
(24). Reduction in muscle strength is not limited to lower
limb muscles; it involves all muscles (1,22). The correlation
found between physical activity and HGS in our study is
also supported by a direct relationship reported between
HGS and physical activity in previous studies of COPD
(25) and community-dwelling individuals (24,26). HGS
has been shown to be a strong and independent predictor
of exercise capacity in patients with heart failure (11). This
supports our finding that 6MWD, a measure of functional
capacity, is significantly correlated with HGS in COPD.
Skeletal muscle dysfunction seen in COPD is not
homogeneous among different muscles (1). The strength
of lower extremity muscles is more severely affected
than upper extremity muscles and handgrip (2,8). This
discrepancy is explained by the frequent use of the upper
extremities in daily activities; thus, upper extremity
muscle strength is relatively conserved (8). In light of
these observations, it can be predicted that slight changes
in HGS might be associated with larger changes in lower
extremity muscle strength. It is suggested that grip
strength measurements may help to identify patients at
risk of deterioration of health (6,20). In our study, reduced
HGS was correlated with a longer hospital stay and shorter
6MWD, which are indicators of reduced health status.

As a predictor of disease severity, pulmonary function
tests revealed lower FEV1 and FEV1/FVC during
exacerbation than stable COPD in our study; however, this
difference did not reach statistical significance. This may
be due to the small sample size of stable COPD patients
in our study. Cortopassi et al. and Shah et al. found a
significant association between HGS and pulmonary
function tests including FVC and FEV1 in stable COPD
subjects (9,11). However, similar to our study, Kaymaz et
al. (25) and Sirguroh and Ahmed (27) did not find any
significant association between HGS and the severity
of airway obstruction. Bernard et al. found that the
relationship of airflow obstruction (FEV1) is weaker with
quadriceps strength than shoulder girdle muscles (5). It
is well known that the severity of obstruction (O) alone
is not a good indicator of disease severity, but BMI (B),
severity of dyspnea (D), and 6MWD (exercise capacity E) are other important parameters and hence the BODE
index is widely used. In our study population, despite a
similar BMI and severity of obstruction, the 6MWD was
shorter in COPD patients with exacerbation.
The 6MWD is reduced by several diseases including
COPD (13) and is significantly correlated with HGS (8).
For a 10-kg increment in HGS, subjects walk approximately
14 m farther (13). The 6MWT can be performed with
subjects who cannot use a cycle ergometer or treadmill
(13). However, some people cannot perform the 6MWT,
either. In this study, 20 subjects could not even walk and
23 subjects stopped before 3 min; these subjects were
older, had a longer duration of COPD, and had a longer
hospital stay. For subjects who cannot perform the 6MWT,
HGS might provide information about overall muscle
endurance and capacity.
The small sample size is a limitation of our study. The
results of our study cannot be generalized to all COPD
subjects, especially those in the stable period.
Our study showed that grip strength was lower in
subjects with COPD exacerbation compared to stable
COPD and non-COPD subjects. The difference observed
in HGS between exacerbated and stable COPD was
not explained by age, comorbidities, the severity of
obstruction, or smoking. Physical inactivity and steroid
use during exacerbation might be the factors affecting low
HGS in exacerbation.
The moderate correlation between HGS and
6MWD during exacerbation led us to suggest that HGS
might provide some information about overall muscle
strength and functional capacity in subjects with COPD
exacerbation. This might be clinically helpful, especially
for subjects who cannot walk or complete the 6MWT.
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